ERJ Open Research最新文献

{"title":"Effect of benralizumab treatment on the airway microbiome in COPD.","authors":"Koirobi Haldar, Vijay Mistry, Mathew Richardson, Corinne Hamblet, Maria Jison, Michael R Barer, Christopher McCrae, Christopher E Brightling","doi":"10.1183/23120541.00802-2024","DOIUrl":"10.1183/23120541.00802-2024","url":null,"abstract":"<p><strong>Background: </strong>One-third of patients with COPD have an eosinophilic inflammatory phenotype. Benralizumab is an afucosylated humanised monoclonal antibody that targets the interleukin-5 receptor α subunit, leading to rapid and near-complete eosinophil depletion <i>via</i> antibody-dependent cellular cytotoxicity. We hypothesised that benralizumab-targeted immune modulation could have an impact on the airway microbiome in COPD. The objective of the present study was to investigate the effect of benralizumab treatment on inflammation and the sputum microbiome in COPD.</p><p><strong>Methods: </strong>Sputum samples from 94 COPD patients enrolled to the GALATHEA trial (NCT02138916) and randomised to receive placebo (33), benralizumab at 100 mg (29) or 30 mg (32) over 52 weeks were analysed at baseline, week 24 and at end of treatment (week 56). Sputum microbiota taxonomic profiles and diversity indices, generated from paired-end Illumina sequencing targeting the 16S rRNA gene, were used for comparative analyses. Linear mixed model analyses were applied to blood and sputum cell counts and eosinophil mediators for within- and between-treatment group analyses.</p><p><strong>Results: </strong>Participants treated with 100 and 30 mg benralizumab, respectively, showed a significant reduction from baseline in both blood and sputum eosinophil counts (blood: p=1.2e-10 and p=8.8e-10; sputum p=0.03 and p=0.004) and eosinophil-derived serum mediators (eosinophil cationic protein: p<3e-09 and p<2e-08; eosinophil-derived neurotoxin: p<8e-12 and p<2e-09). No significant changes in the composition or diversity of the sputum microbiome were observed.</p><p><strong>Conclusions: </strong>In this study, the airway microbiome measured in sputum was unaffected by a targeted reduction of eosinophilic inflammation with benralizumab treatment.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973710/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal recovery trajectories and ventilatory modalities in COVID-19 acute respiratory distress syndrome survivors.","authors":"Jessica González, Iván D Benítez, Sally Santisteve, Anna Vila, Maria Aguilà, Gerard Torres, Anna Sánchez-Cucó, Mar Malla-Bañeres, Anna Moncusí-Moix, Jordi de Batlle, Esther Gracia-Lavedan, Adrián Ceccato, Ricard Ferrer, Anna Motos, Jordi Riera, Laia Fernández, Rosario Menéndez, José Ángel Lorente, Oscar Peñuelas, Dario García, Oriol Roca, Yhivian Peñasco, Pilar Ricart, Maria Cruz Martin Delgado, Luciano Aguilera, Alejandro Rodríguez, Maria Victoria Boado Varela, Felipe Pérez-García, Juan Carlos Pozo-Laderas, Jordi Solé-Violan, Berta Adell-Serrano, Mariana Andrea Novo, José Barberán, Rosario Amaya Villar, David de Gonzalo-Calvo, Antoni Torres, Ferran Barbé, Ferran Roche-Campo","doi":"10.1183/23120541.00770-2024","DOIUrl":"10.1183/23120541.00770-2024","url":null,"abstract":"<p><strong>Background: </strong>The impact of different ventilatory support modalities and timing of intubation on longitudinal lung recovery trajectories in patients with severe coronavirus disease 2019 (COVID-19) is unknown.</p><p><strong>Methods: </strong>This was a multicentre, prospective observational study conducted in 52 Spanish intensive care units (ICUs) involving critically ill COVID-19 patients admitted between 25 February 2020 and 8 February 2021. 1854 COVID-19 patients were followed after hospital discharge at 3, 6 and 12 months with diffusing capacity of the lung for carbon monoxide (<i>D</i> _LCO) measurements and chest imaging. Patients were classified regarding the ventilatory support received during the ICU stay: noninvasive mechanical ventilation (NIMV), high-flow nasal cannula (HFNC) and invasive mechanical ventilation (IMV), divided into early IMV (intubation within 24 h) and late IMV (intubation after 24 h). The primary objective was to evaluate the impact of the different respiratory support modalities during the ICU stay and the time of intubation on <i>D</i> _LCO measurements and their recovery trajectories over a 1-year follow-up. Secondary outcomes included other pulmonary function parameters and chest imaging findings.</p><p><strong>Results: </strong>A total of 360 (19.4%) and 290 (15.6%) patients received HFNC and NIMV, respectively. 1204 (64.9%) patients underwent IMV; 966 received early IMV and 238 received late IMV. The latter exhibited a significantly worse percentage predicted <i>D</i> _LCO during the 1-year follow-up with adjusted differences of 6.9 (95% CI 3.9-10; p<0.001), 4.2 (95% CI 1.1-7.2; p=0.007) and 4.9 (95% CI 1.7-8.2; p=0.003) at 3, 6 and 12 months compared with early IMV. NIMV patients exhibited greater lung damage at follow-up than those under HFNC with an adjusted difference of percentage predicted <i>D</i> _LCO of 5.2 (95% CI 1.7-8.7; p=0.003) at 6 months and greater presence of radiological abnormalities during follow-up. Matched and sensitivity analysis showed results consistent with those reported.</p><p><strong>Conclusions: </strong>Delay in intubation implies the worst outcomes; however, patients with NIMV exhibited a slower lung recovery in terms of <i>D</i> _LCO measurements and more radiological abnormalities compared with HFNC patients. These results should be used to optimise follow-up protocols for COVID-19 acute respiratory distress syndrome (ARDS) survivors.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973715/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-viral lung diseases: the microbiota as a key player.","authors":"Sabine V Stadler, Christophe von Garnier, Niki D Ubags","doi":"10.1183/23120541.00560-2024","DOIUrl":"10.1183/23120541.00560-2024","url":null,"abstract":"<p><p>Viral infections of the respiratory tract can lead to chronic lung injury through immunopathological mechanisms that remain unclear. Communities of commensal bacteria colonising the respiratory tract, known as the respiratory tract microbiota, are altered in viral infections, which can contribute to inflammation, lung epithelial damage and subsequent development of lung disease. Emerging evidence on post-viral lung injury suggests an interplay between viral infections, immune responses and airway microbiota composition in the development of viral-induced lung diseases. In this review, we present the clinical characteristics of post-viral lung injury, along with the underlying immunopathological mechanisms and host-bacteria interactions, with a focus on influenza virus, respiratory syncytial virus and coronaviruses. Additionally, considering the important role of the airway microbiota in viral-induced pulmonary sequelae, we suggest key areas for future research on respiratory microbiota involvement in the development of post-viral lung diseases.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Should all patients with COPD be treated with inhaled triple therapy?","authors":"Don D Sin, Mohsen Sadatsafavi","doi":"10.1183/23120541.00827-2024","DOIUrl":"10.1183/23120541.00827-2024","url":null,"abstract":"<p><p><b>Triple therapy should be initiated earlier in the course of COPD</b> https://bit.ly/3Nh9W6j.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973708/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delaying disease progression in COPD with early escalation to triple therapy: a modelling study (DEPICT-2).","authors":"Dave Singh, Diego Fabian Litewka, Joan B Soriano, Adrian Rendon, Frederico Leon Arrabal Fernandes, Rafael Páramo-Arroyo, Tim Trinidad, Hakan Günen, Sudeep Acharya, Bhumika Aggarwal, Gur Levy, Chris Compton, Abdelkader El Hasnaoui, Peter Daley-Yates","doi":"10.1183/23120541.00438-2024","DOIUrl":"10.1183/23120541.00438-2024","url":null,"abstract":"<p><strong>Introduction: </strong>In patients with COPD, dual bronchodilator (long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA)) and triple therapy (inhaled corticosteroid/LAMA/LABA) reduce the risk of exacerbations and lung function decline in the short-mid-term, but their long-term impact is unknown. This modelling study explores long-term impact of these therapies on lung function decline, quality of life (QoL) and all-cause mortality.</p><p><strong>Methods: </strong>This modelling approach used a longitudinal nonparametric superposition model using published data regarding exacerbations, QoL (assessed by St George's Respiratory Questionnaire (SGRQ)) and mortality. The model simulated disease progression from 40 to 75 years of age and assessed the impact of initiating dual bronchodilator at age 45 years (\"LAMA/LABA only\" group) and escalation to triple therapy at age 50 years (\"Escalation to triple\" group) on forced expiratory volume in 1 s (FEV₁) decline, QoL and mortality.</p><p><strong>Results: </strong>Model simulation predicted that by 75 years of age, \"LAMA/LABA only\" preserves 159.1 mL of FEV₁ <i>versus</i> no treatment, while \"Escalation to triple\" preserves an additional 376.5 mL and 217.3 mL of FEV₁ <i>versus</i> no pharmacotherapy and \"LAMA/LABA only\", respectively. In \"LAMA/LABA only\", the SGRQ score reduces (-3.2) <i>versus</i> no treatment, which further reduces to -7.5 in \"Escalation to triple\". In \"LAMA/LABA only\", mortality reduces by 5.4% by 75 years <i>versus</i> no treatment, while the \"Escalation to triple\" shows further decrease in mortality by 12.0%.</p><p><strong>Conclusion: </strong>Early pharmacotherapy initiation and escalation from dual bronchodilator to triple therapy could slow disease progression by preserving lung function and improving QoL and survival in patients with COPD.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic factors after therapeutic bronchoscopy for tracheo- or broncho-oesophageal fistulas: results from the EpiGETIF registry.","authors":"Juliette Edme, Clément Fournier, Benoit Lepage, Claudia Zea Obando Ep Chateau, Laurent Cellerin, Frederic Wallyn, Gavin Plat, Valentin Héluain, Samy Lachkar, Thomas Egenod, Christophe Gut Gobert, Loic Perrot, Christine Lorut, Aurélie Lefebvre, Jean Michel Vergnon, Valerian Bourinet, Pascalin Roy, Julien Legodec, Hervé Dutau, Nicolas Guibert","doi":"10.1183/23120541.00435-2024","DOIUrl":"10.1183/23120541.00435-2024","url":null,"abstract":"<p><strong>Introduction: </strong>Treatment of malignant tracheo- or broncho-oesophageal fistulas (TOF) using therapeutic bronchoscopy (TB) is not standardised and its outcomes are poorly described. This study aimed to analyse the characteristics of patients treated with TB for a TOF and to identify prognostic factors.</p><p><strong>Methods: </strong>We analysed data from 96 patients undergoing TB for TOF entered in the EpiGETIF registry between January 2019 and December 2022.</p><p><strong>Results: </strong>The mean age was 61.4 years. Median survival after TB was 2.40 months (95% CI 1.81-3.32). Histology was mainly represented by oesophageal (72%) and lung (23%) cancers and did not influence prognosis (p=0.15), whereas smoking did (2.17 <i>versus</i> 3.32 months for nonsmokers, p=0.04). Patients with poor <i>performance status</i> (Eastern Cooperative Oncology Group >2) had shorter survival (1.99 <i>versus</i> 3.02 months, p=0.04). 69% of patients had already received oncologic treatment, with no difference in survival (3.02 <i>versus</i> 2.21 months for treatment-naive patients, p=0.14). Neither the localisation (trachea 61.5%, left main bronchus 34.4%, other 4.1%) nor the size of the fistulas (23% <5 mm, 20% 5-10 mm, 54% >10 mm) impacted survival (p=0.91 and p=0.83, respectively). An airway stent (AS) was placed in 92.7% of patients, mainly self-expanding metallic stents (45%). Patients treated with both an oesophageal stent and AS had a better prognosis than patients treated with an AS alone (2.88 <i>versus</i> 1.77 months, respectively, p=0.02).</p><p><strong>Conclusion: </strong>Survival of patients treated with TB for a TOF is very poor, and is impacted by smoking, performance status and the presence of an oesophageal stent.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-inflammatory effects of tiotropium in COPD: a randomised double-blind trial.","authors":"Lisa H van Smoorenburg, Tatiana Karp, Benedikt Ditz, Wouter H van Geffen, Victor Guryev, Ali Almusa, Loes Kistemaker, Reinoud Gosens, Maarten van den Berge, Huib A M Kerstjens","doi":"10.1183/23120541.00735-2024","DOIUrl":"10.1183/23120541.00735-2024","url":null,"abstract":"<p><strong>Background: </strong>COPD is a major global health issue characterised by respiratory symptoms and exacerbations, significantly impacting mortality and quality of life. Muscarinic antagonists are known to prevent exacerbations, possibly by mitigating airway inflammation. This study evaluated the anti-inflammatory effects of tiotropium in patients with COPD by examining inflammatory protein profiles in sputum and blood, and genome-wide expression in sputum.</p><p><strong>Methods: </strong>We conducted the prospective, double-blind, randomised controlled ANTIOFLAM trial. Patients with COPD Global Initiative for Chronic Obstructive Lung Disease stage II or worse, aged ≥40 years and a smoking history of ≥10 pack-years were included. After a 4-week washout period of inhaled corticosteroids and anticholinergics, participants were randomised to 6 weeks of treatment with placebo or tiotropium (soft mist inhaler, 5 µg daily). Our primary end-point was a decrease of sputum interleukin (IL)-6 and IL-8 levels in the tiotropium group when compared to the placebo group.</p><p><strong>Results: </strong>We evaluated samples of 33 participants (n=17 placebo and n=16 tiotropium). Changes in sputum proteins IL-6 and IL-8 were significantly higher after treatment with tiotropium when compared to placebo (p<0.05). Differential expression analysis did not reveal gene expression differences including IL-6 and IL-8.</p><p><strong>Conclusion: </strong>We did not find tiotropium to have anti-inflammatory effects in sputum or blood of patients with COPD. In contrast, we found 6 weeks of treatment with tiotropium to increase the concentration of almost all tested sputum inflammatory proteins when compared to placebo, while RNA expression levels did not change.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intra-breath respiratory mechanics of prematurity-associated lung disease phenotypes in school-aged children.","authors":"Michael Cousins, Kylie Hart, Bence Radics, A John Henderson, Zoltán Hantos, Peter D Sly, Sailesh Kotecha","doi":"10.1183/23120541.00840-2024","DOIUrl":"10.1183/23120541.00840-2024","url":null,"abstract":"<p><strong>Background: </strong>Intra-breath oscillometry potentially offers detailed information regarding airway function, with increasing magnitude of difference between resistance and reactance at end-expiration to end-inspiration potentially associated with obstructive airway disease, but less is known about specific respiratory mechanics in preterm-born children using this methodology. We investigated whether different spirometry phenotypes of prematurity-associated lung disease (PLD) have specific intra-breath oscillometry features.</p><p><strong>Methods: </strong>167 school-aged (7-12 years) children, 14 with prematurity-associated obstructive lung disease (POLD; forced expiratory volume in 1 s (FEV₁) <lower limit of normal (LLN), FEV₁/forced vital capacity (FVC) <LLN), 11 with prematurity-associated preserved ratio impaired spirometry (pPRISm; FEV₁ <LLN, FEV₁/FVC ≥LLN), 90 preterm controls (FEV₁ ≥LLN) and 52 term controls, performed intra-breath oscillometry at baseline, following maximal cardiopulmonary exercise testing and following post-exercise bronchodilation.</p><p><strong>Results: </strong>Children with POLD showed greater resistance and more negative reactance throughout the respiratory cycle, including at zero-flow states of end-expiration and end-inspiration. The difference between end-expiration and end-inspiration did not show differences between groups until corrected for tidal volume, whereby children with POLD and pPRISm both demonstrated approximately two-fold greater difference compared to both preterm and term controls for resistance (2.24 and 2.22 <i>versus</i> 1.28 and 1.11 hPa·s·L^-1, respectively), and in particular a greater magnitude of difference for reactance for children with POLD <i>versus</i> preterm and term controls only (-1.58 <i>versus</i> -0.26 and 0.03 hPa·s·L^-1, respectively).</p><p><strong>Conclusions: </strong>Intra-breath respiratory mechanics for preterm-born children with an obstructive lung phenotype have greater impedance throughout the respiratory cycle, features different to those observed in children with other wheeze phenotypes including preschool wheeze and asthma.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementing pulmonary arterial hypertension screening among <i>TBX4</i> mutation carriers: a timely endeavour.","authors":"David Montani, Julien Grynblat, Florence Coulet, Damien Bonnet, Antoine Beurnier, Marc Humbert","doi":"10.1183/23120541.00760-2024","DOIUrl":"10.1183/23120541.00760-2024","url":null,"abstract":"<p><p><b>Systematic genetic counselling for <i>TBX4</i> carriers and their relatives enables screening for small patella syndrome and early diagnosis of pulmonary arterial hypertension</b> https://bit.ly/4eKaPzY.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955912/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Right ventricular-pulmonary arterial coupling predicts mortality in precapillary pulmonary hypertension.","authors":"Athiththan Yogeswaran, René Petermann, Nils C Kremer, Simon Schäfer, Zvonimir A Rako, Rebecca R Vanderpool, Ryan J Tedford, Khodr Tello","doi":"10.1183/23120541.00685-2024","DOIUrl":"10.1183/23120541.00685-2024","url":null,"abstract":"<p><p><b>RV-PA coupling, as reflected by the <i>E</i> _es/<i>E</i> _a ratio, holds substantial clinical relevance and augments the current prognostic assessment in patients with PAH and CTEPD with PH</b> https://bit.ly/4dyKPGJ.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}